Director of Thoracic Oncology
Oncology
Dr. Corey J. Langer, MD
|
|
Give Review
Dr. Corey J. Langer practices Oncology. He studied medicine at Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. He has 6 awards "Philadelphia Magazine", "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACP)" and "Super Doctor". Corey J. Langer is a published physician. He published 97 publications, including: 'PILOT AND FEASIBILITY TRIAL OF IMMUNO-GENE THERAPY OF MALIGNANT MESOTHELIOMA USING INTRAPLEURAL DELIVERY OF ADENOVIRUS- INTERFERON-ALPHA COMBINED WITH CHEMOTHERAPY.' Corey Langer accepts Medicare payments and is listed with Medicare.gov.
Publications
- PILOT AND FEASIBILITY TRIAL OF IMMUNO-GENE THERAPY OF MALIGNANT MESOTHELIOMA USING INTRAPLEURAL DELiverY OF ADENOVIRUS- INTERFERON-ALPHA COMBINED WITH CHEMOTHERAPY.
- Longitudinal Analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
- Warthin's Tumors and Their Relationship to Lung Cancer.
- Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBr...
- Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung Cancer: A hypothesis-generating study.
- Strategies to prevent brain metastasis in high-risk non-small-cell lung Cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
- Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative On...
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced ...
- Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung Cancer.
- Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung Cancer? A cross-sectional survey.
- Emerging Immunotherapies in the Treatment of Non-Small Cell Lung Cancer (NSCLC): The Role of Immune Checkpoint Inhibitors.
- Understanding the experience of living with non-small-cell lung Cancer (NSCLC): a qualitative study.
- Multidisciplinary Therapy of Stage IIIA Non-Small-Cell Lung Cancer: Long-term Outcome of Chemoradiation With or Without Surgery.
- Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal Cancer.
- Treatment of lung Cancer in the elderly patient.
- Complementary and alternative medicine use and benefit finding among Cancer patients.
- Stage Migration in Planning PET/CT Scans in Patients Due to Receive Radiotherapy for Non-Small-Cell Lung Cancer.
- Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?
- Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung Cancer: is afatinib better or simply newer?
- Immunological effects of the TGFβ-blocking antibody GC1008 in Malignant pleural mesothelioma patients.
- Determinants of Survival in Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapies.
- ACR Appropriateness Criteria Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent.
- Is a Cancer diagnosis a teachable moment for the patient's relative who smokes?
- Evaluation of EGFR mutation status in cytology specimens: an institutional experience.
- ACR Appropriateness Criteria® Radiation Therapy for Small-Cell Lung Cancer.
- Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma.
- Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell Carcinoma of the head and neck.
- Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer.
- The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung Cancer: Long-term follow-up of Radiation Therapy ...
- Penetration of Recommended Procedures for Lung Cancer Staging and Management in the United States Over 10 Years: A Quality Research in Radiation Oncology Survey.
- Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenoCarcinoma of the lung.
- Utilization of Supportive and Palliative Care Services among Oncology Outpatients at One Academic Cancer Center: Determinants of Use and Barriers to Access.
- Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung Cancer (NSCLC).
- Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated With Definitive Radiation: Dosimetric Analysis and Clinical Implications.
- Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung Cancer.
- A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Tox...
- Hematologic outcomes and blood utilization in Cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from ...
- ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung Cancer.
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.
- Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in Th...
- Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.
- Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma.
- Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
- The evolving role of histology in the management of advanced non-small-cell lung Cancer.
- ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung.
- Molecular analysis of non-small cell lung Cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
- Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung Cancer: a single-institution experience.
- The influence of gender, race, and marital status on survival in lung Cancer patients: analysis of Radiation Therapy Oncology Group trials.
- Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable n...
- ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung Cancer: good performance status/definitive intent.
- Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and ...
- Safety of bevacizumab in patients with non-small-cell lung Cancer and brain metastases.
- Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and phar...
- National Cancer Database report on Cancer of the head and neck: 10-year update.
- Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, local...
- Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung Cancer: clinical and pharmacogenomic results from SWOG S0124.
- The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung Cancer and epidermal growth factor receptor mutation.
- Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung Cancer patients with brain metastases...
- ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung Cancer: poor performance status or palliative intent.
- Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung Cancer: an a...
- Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung Cancer (NSCLC): results of OPN-017.
- Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung Cancer? Insights from the 2008 American Society of Clinical Oncology Meeting.
- Promising survival in patients with recurrent non-small cell lung Cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Targeted therapy in head and neck Cancer: state of the art 2007 and review of clinical applications.
- Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 pati...
- Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive Malignant pleural mesothelioma.
- Population characteristics and prognostic factors in metastatic non-small-cell lung Cancer: a Fox Chase Cancer Center retrospective.
- Restrictive eligibility limits access to newer therapies in non-small-cell lung Cancer: the implications of Eastern Cooperative Oncology Group 4599.
- Cooperative group portfolio in locally advanced non-small-cell lung Cancer: are we making progress?
- Zoledronic acid and survival in patients with metastatic bone disease from lung Cancer and elevated markers of osteoclast activity.
- The emerging role of cetuximab in head and neck Cancer: a 2007 perspective.
- Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid Tumors.
- Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell Carcinoma of the ...
- The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients.
- Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung Carcinoma.
- Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung Cancer.
- Salvage therapy with vinorelbine in advanced non-small-cell lung Cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature.
- A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cel...
- Successful coronary artery bypass grafting after concurrent chemoradiation therapy in a patient with non-small-cell lung Cancer: case report and review of the literature.
- Impact of zoledronic acid on renal function in patients with Cancer: Clinical significance and development of a predictive model.
- Laryngeal Cancer in the United States: changes in demographics, patterns of care, and survival.
- Targeting anemia in patients with lung Cancer.
- Surgical patterns of care in operable lung Carcinoma treated with radiation.
- Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung Cancer.
- Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, o...
- Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report.
- The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Onco...
- Current management of Brain metastases, with a focus on systemic options.
- Toxicity and outcome analysis of patients with recurrent head and neck Cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and pa...
- Role of zoledronic acid in the setting of bone metastases from non-small-cell lung Cancer.
- Response to temozolomide in second-line treatment of recurrent nonsmall cell lung Carcinoma: case report.
- CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.
- Irinotecan in advanced lung Cancer: focus on North American trials.
- Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metas...
Schools
Boston University School Of Medicine
Graduate Hospital
Presby Hospital University Penn
Fox Chase Canc Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Philadelphia Magazine
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Super Doctor
Education
-
Fox Chase Cancer Center -
University of Pennsylvania -
Boston University School of Medicine
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center
Drug Facts
| NPI NUMBER | 1811918501 | |
| NPPES Provider LastName | LANGER | |
| NPPES Provider FirstName | COREY | |
| NPPES Provider ZIPCode | 191112434 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 486.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 88.0 | |
| Percent Opioid Claims | 18.11 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811918501 |
| Last Name Of The Provider | LANGER |
| First Name Of The Provider | COREY |
| View All |
Similar Doctors
|
|
Dr. Mary K. Vaske, MD |
|
|
Dinah Essilfie, CRNP |
|
|
Pooja Suresh |
|
|
Dr. Amishi Y. Shah, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monica M. Bessler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin O. Aakhus, MD |
|
|
Dr. Lainie Martin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven J. Cohen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Demichele, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gataree Ngarmchamnanrith, MD |
|
|
Dr. Esha Kaul, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah R. Goodyear, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula D. Ryan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert F. Ozols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sameh R. Gaballa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel M. Geynisman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Crystal S. Denlinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shayma M. Kazmi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer M. Matro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence F. Brass, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nevena Damjanov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravi Amaravadi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ronald I. Cantor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol K. Tweed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jakub Svoboda, MD
This Doctor is OpenDoctor Recommended.
|